PT  - JOURNAL ARTICLE
AU  - Mseka, Upendo L.
AU  - Mandolo, Jonathan
AU  - Nyoni, Kenneth
AU  - Divala, Oscar
AU  - Kambalame, Dzinkambani
AU  - Mapemba, Daniel
AU  - Kamzati, Moses
AU  - Chibwe, Innocent
AU  - Henrion, Marc Y. R.
AU  - Manda, Kingsley
AU  - Thindwa, Deus
AU  - Mvula, Memory
AU  - Odala, Bright
AU  - Kamng’ona, Raphael
AU  - Dzinza, Nelson
AU  - Jere, Khuzwayo C.
AU  - Feasey, Nicholas
AU  - Ho, Antonia
AU  - Amoah, Abena S.
AU  - Gordon, Melita
AU  - Swarthout, Todd D
AU  - Crampin, Amelia
AU  - Heyderman, Robert S.
AU  - Kagoli, Matthew
AU  - Chitsa-Banda, Evelyn
AU  - Mitambo, Collins
AU  - Phuka, John
AU  - Chilima, Benson
AU  - Kasambara, Watipaso
AU  - Jambo, Kondwani C.
AU  - Chauma-Mwale, Annie
TI  - Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi
AID  - 10.1101/2022.08.22.22279060
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.22.22279060
4099  - http://medrxiv.org/content/early/2022/08/23/2022.08.22.22279060.short
4100  - http://medrxiv.org/content/early/2022/08/23/2022.08.22.22279060.full
AB  - Background The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends of hospitalisations and deaths are needed to aid locally relevant public health policy decisions.Methods We conducted a population-based serosurvey from December 27, 2021 to January 17, 2022, in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Primary sampling units (PSU) were selected using probability proportionate to the number of households based on the 2018 national census, followed by second-stage sampling units that were selected from listed households. A random systematic sample of households was selected from each PSU within the 7 districts. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including cases, hospitalizations and deaths from April 1, 2021 through April 30, 2022, collected using the routine national COVID-19 reporting system.Results Serum samples were analysed from 4619 participants (57% female; 65% aged 14 to 50 years), of whom 1018 (22%) had received a COVID-19 vaccine. The overall assay-adjusted seroprevalence was 86.3% (95% confidence interval (CI), 85.1% to 87.5%). Seroprevalence was lowest among children <13 years of age (66%) and highest among adults 18 to 50 years of age (82%). Seroprevalence was higher among vaccinated compared to unvaccinated participants (96% vs. 77%; risk ratio, 6.65; 95% CI, 4.16 to 11.40). Urban residents were more likely to test seropositive than those living in rural settings (91% vs. 78%; risk ratio, 2.81; 95% CI, 2.20 to 3.62). National COVID-19 data showed that at least a two-fold reduction in the proportion of hospitalisations and deaths among the reported cases in the fourth wave compared to the third wave (hospitalization, 10.7% (95% CI, 10.2 to 11.3) vs 4.86% (95% CI, 4.52 to 5.23), p<0.0001; deaths, 3.48% (95% CI, 3.18 to 3.81) vs 1.15% (95% CI, 1.00 to 1.34), p<0.0001).Conclusion We report reduction in proportion of hospitalisations and deaths from SARS-CoV-2 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2 seroprevalence but low COVID-19 vaccination coverage. These findings suggest that COVID-19 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to targeted vaccination of at-risk populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Bill and Melinda Gates Foundation (INV-039481).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Health Sciences Research Committee (NHSRC) (Protocol #21/02/2671) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors